GLP-1 weight loss drugs are shrinking residual limbs. Clinicians at the AOPA assembly are already adapting.

GLP-1 receptor agonists, the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), cause rapid, substantial weight loss. For people who wear prostheses, that weight does not come only from the places you might expect. A share of it comes off the residual limb, and when the residual limb shrinks, the socket stops fitting the way it was built to fit.

This is not a hypothetical. The American Orthotic and Prosthetic Association held a session at its national assembly in Las Vegas last month on exactly this: how weight loss drugs are landing in O&P clinics. The O&P EDGE reported on a poll of clinicians who attended, asking what the biggest care challenge has been with rapid weight loss medications. Socket loosening was the top answer (33 percent). Increased volume fluctuation tied it (33 percent). Skin and alignment issues came in at 25 percent. Needing more socket adjustments came in at 8 percent.

The fact that the AOPA held a session on this at all is the signal worth reading. These are practitioners across different clinics reporting the same pattern.

Why a socket cannot just adapt on its own

A prosthetic socket is fitted to a specific residual limb volume at a specific time. The fitting accounts for some expected variation: good prosthetists build in liner choices and padding strategies for day-to-day swings, and they counsel new wearers on using prosthetic socks to compensate for minor volume loss across a wearing day.

What GLP-1 medications introduce is a different kind of change: faster and more sustained than the typical volume shift. Users lose a meaningful percentage of body weight over months rather than years. The residual limb is part of that redistribution. A socket fitted before starting the medication can become noticeably loose within three to six months, well before the normal replacement cycle.

A loose socket creates piston motion on every step: the residual limb moves up and down inside the socket instead of staying seated. That friction generates the skin and alignment problems in the AOPA poll. They are not separate issues from socket loosening; they are what socket loosening eventually produces.

Volume fluctuation complicates it further. If the limb is still actively changing, there is no stable new volume to fit to. Some weeks the socket feels tolerable. Some weeks it does not. Managing that with extra socks has limits, and it does not address the alignment changes that come with significant volume loss.

What to do if you are on or starting a GLP-1 drug

Tell your prosthetist before you start, not after the socket starts to feel loose. The change is gradual enough that it is easy to delay addressing it, and prosthetists can only document what they know about.

Getting ahead of the problem with an appointment at two months and again at four months lets the prosthetist track volume change, adjust liner and padding strategies, and start building the documentation trail that an eventual socket replacement will need. Insurance eligibility for a replacement has timing rules, and a replacement driven by medically documented fit failure tied to a specific treatment is a different claim argument than requesting one at the standard interval.

If you are already on a GLP-1 drug and have been adding socks to compensate for looseness, that is a reason to schedule a fitting appointment rather than keep stacking. Socks handle minor volume loss; they do not handle the alignment shift that comes with significant residual limb change.

None of this is a reason to avoid these medications if your physician is recommending them. It is a reason to treat socket management as part of the medication plan rather than a separate thing to deal with later.

This article does not constitute individual clinical, medical, or fitting advice. Socket management decisions depend on your specific limb, socket, and clinical history. Work through them with your own prosthetist and prescribing team.